News: Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

1,369.05INR
6:29am EDT
Price Change (% chg)

Rs23.75 (+1.77%)
Prev Close
Rs1,345.30
Open
Rs1,351.00
Day's High
Rs1,375.00
Day's Low
Rs1,351.00
Volume
556,462
Avg. Vol
506,432
52-wk High
Rs1,442.15
52-wk Low
Rs840.40

Search Stocks
Select another date:

Tue, Oct 28 2014

Lupin Q2 profit up as US, India sales rise

MUMBAI, Oct 28 - Indian generic drugmaker Lupin Ltd reported a 54 percent jump in second-quarter profit beating analysts estimates, helped by robust sales in its domestic business and the United States, its largest market.

Merck KGaA agrees to market Lupin drugs in emerging countries

FRANKFURT - German drugmaker Merck KGaA said it struck a deal with Lupin Limited to market some of the Indian drugmaker's cardiovascular and diabetes treatments in emerging markets.

Merck KGaA agrees to market Lupin drugs in emerging countries

FRANKFURT, Sept 16 - German drugmaker Merck KGaA said it struck a deal with Lupin Limited to market some of the Indian drugmaker's cardiovascular and diabetes treatments in emerging markets.

CORRECTED-India's Lupin in deal to market U.S. firm Salix's drugs in Canada

(Corrects to say Salix will get upfront payment from Lupin in second paragraph)

INDIA PRESS-Lupin targets 30 bln rupees India sales by year-end-Economic Times

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aby Jose Koilparambil in Bangalore)

UPDATE 1-Lupin expects India sales to grow 18-20 pct in fiscal 2015

* Q1 net profit up 56 pct at 6.25 bln rupees, beats estimates

India's Lupin Q1 net up 56 pct on higher U.S. drug sales

MUMBAI, July 30 - Lupin Ltd, India's fourth-largest drugmaker by sales, reported a higher-than-expected profit in the first quarter, helped mainly by higher sales in the United States and India, and lower expenses.

Exclusive - India's Lupin, U.S. firms weigh bids for GSK's mature drugs: sources

LONDON/MUMBAI - Indian generics firm Lupin , some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being auctioned by GlaxoSmithKline (GSK) , five sources familiar with the matter said.

INDIA PRESS-Lupin to exit from weaker brands, to buy stronger ones-Mint

Note: Reuters has not verified this story and does not vouch for its accuracy. (Compiled by Aby Jose Koilparambil in Bangalore)

Select another date:

Press Releases

Search Stocks